Limitations of Chromogranin A in clinical practice
- 6 January 2012
- journal article
- Published by Taylor & Francis Ltd in Biomarkers
- Vol. 17 (2), 186-191
- https://doi.org/10.3109/1354750x.2012.654511
Abstract
Context: Usefulness of circulating Chromogranin A (CgA) for the diagnosis of neuroendocrine tumors (NEN) is controversial. The aim of the present study was to assess the actual role of this marker as diagnostic tool. Methods: Serum blood samples were obtained from 42 subjects affected with NEN, 120 subjects affected with non-endocrine neoplasias (non-NEN) and 100 non-neoplastic subjects affected with benign nodular goitre (NNG). Determination of CgA was performed by means of immunoradiometric assay. Results: The CgA levels among NEN-patients were not significantly different from NNG and non-NEN subjects. The Receiver operating characteristic (ROC) curves analysis failed to identify a feasible cut-off value for the differential diagnosis between NEN and the other conditions. Conclusion: Serum CgA is not helpful for the first-line diagnosis of NEN.Keywords
This publication has 20 references indexed in Scilit:
- The Pathologic Classification of Neuroendocrine Tumors A Review of Nomenclature, Grading, and Staging SystemsPancreas, 2010
- Chromogranins as regulators of exocytosisJournal of Neurochemistry, 2010
- The biological characterization of neuroendocrine tumors: The role of neuroendocrine markersJournal of Endocrinological Investigation, 2008
- Pulmonary and extrapulmonary poorly differentiated large cell neuroendocrine carcinomasCancer, 2007
- Chromogranin A: Is It a Useful Marker of Neuroendocrine Tumors?Journal of Clinical Oncology, 2007
- Proton pump inhibitors and gastric neoplasiaGut, 2006
- Chromogranin A and the α -subunit of glycoprotein hormones in medullary thyroid carcinoma and phaeochromocytomaBritish Journal of Cancer, 2001
- Plasma Chromogranin A in Patients with Multiple Endocrine Neoplasia Type 1Journal of Clinical Endocrinology & Metabolism, 1999
- Prospective study of the value of serum chromogranin A or serum gastrin levels in the assessment of the presence, extent, or growth of gastrinomasCancer, 1999
- Endocrine cells in colorectal adenocarcinomas: Incidence, hormone profile and prognostic relevanceInternational Journal of Cancer, 1993